As of June 2024, the National Institute for Health and Care Excellence (NICE) has recommended the use of Mounjaro as a treatment for overweight or obesity.
According to the new draft NICE guidelines, Mounjaro is now advised for overweight and obesity treatment within the NHS for individuals with a BMI of at least 35kg/m2 and who have associated medical conditions. It's important to note that individuals from Black African, African-Caribbean, Asian, South Asian, Chinese, and Middle Eastern backgrounds may be eligible at a lower BMI if they have relevant medical conditions.
In line with the guidelines, Mounjaro may be discontinued if a patient's weight loss is less than 5% after six months. Unlike other weight loss medications like Wegovy and Saxenda, there is no specified time limit for the duration of Mounjaro treatment, and it is not mandatory for it to be administered through specialist weight management services.
NICE is scheduled to convene on 13 August to evaluate feedback on the draft decision before finalizing the guidelines for publication.